# US 2010/0249035 A1 · Peptides, compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0249035 A1
- Document ID: US20100249035A1
- Status: Published application
- Kind: A1
- Application number: 12/449,950
- Filed: 2008-03-07
- Published: 2010-09-30
- Earliest claimed: 2007-03-07
- Assignees: The Queen's University of Belfast
- Inventors: Christopher Shaw; Tianbao Chen; Martin O'Rourke; Brian Walker; David Hirst
- Web page: https://patentgrep.com/patent/US20100249035A1

## CPC

- C07K 7/18: Kallidins; Bradykinins; Related peptides
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/00: Drugs for dermatological disorders
- C07K 14/47: from mammals
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described is an N-terminal hexapeptide fragment of maximakinin, QUB 698.8, which exhibits potent tissue selective actions on smooth muscle. It demonstrates a high degree of selectivity for arterial smooth muscle over small intestinal smooth muscle, causing potent relaxation of arterial smooth muscle, while causing less potent contraction of ileal smooth muscle. It may be used treatment of diseases of the cardiovascular system and in promotion of angiogenesis.

## Claims

### Claim 1

A pro-angiogenic peptide, wherein said pro-angiogenic peptide is QUB698.8 or a biologically active fragment or derivative thereof.

### Claim 2 (depends on 1)

The peptide according to claim 1, wherein the peptide consists of the amino acid sequence:
Asp-Leu-Pro-Lys-Ile-Asn.
(SEQ ID NO: 2)

### Claim 3 (depends on 1)

The peptide according to claim 1, wherein the peptide consists of the amino acid sequence
Asn-Ile-Lys-Pro-Leu-Asp
(SEQ ID NO: 9)

### Claim 4 (depends on 1)

The peptide according to claim 1, wherein the EC50 of the peptide at arterial smooth muscle receptors is less than the EC50 of maximakinin at arterial smooth muscle receptors.

### Claim 5 (depends on 1)

The peptide according to claim 1, wherein the EC50 of the peptide at small intestinal receptors is more than the EC50 of maximakinin at small intestinal receptors.

### Claim 6 (depends on 1)

A polynucleotide encoding a peptide according to claim 1, wherein said polynucleotide does not encode a polypeptide comprising an amino acid sequence shown as Sequence ID No: 1.

### Claim 7 (depends on 1, 6)

A method of promoting vasodilation in a tissue, comprising administering a peptide according to claim 1 or a polynucleotide according to claim 6 to said tissue.

### Claim 8 (depends on 1, 6)

A method of treating cardiovascular disease comprising administering a peptide according to claim 1 or a polynucleotide according to claim 6 to a patient in need thereof.

### Claim 9 (depends on 1, 6)

A method of promoting angiogenesis in a tissue comprising the step of administering a peptide according to claim 1 or a polynucleotide according to claim 6 to said tissue.

### Claim 10 (depends on 1, 6)

A method of promoting or accelerating tissue repair or wound healing comprising administering a peptide according to claim 1 or a polynucleotide according to claim 6 to a subject in need thereof.

### Claim 11 (depends on 1, 6)

A pharmaceutical composition comprising a peptide according to claim 1 or a polynucleotide according to claim 6 and a pharmaceutically acceptable carrier or excipient.

### Claim at position 12

-18. (canceled)

### Claim 19 (depends on 8)

The method according to claim 8, wherein said cardiovascular disease is ischaemic disease.

### Claim 20 (depends on 8)

The method according to claim 8, wherein said cardiovascular disease is vascular disease or vascular damage.

### Claim 21 (depends on 10)

The method according to claim 10, wherein said tissue repair or wound healing is repair or healing of an ulcer.

### Claim 22 (depends on 10)

The method according to claim 10, wherein said tissue repair or wound healing is repair or healing of a burn.

### Claim 23 (depends on 10)

The method according to claim 10, wherein said tissue repair or wound healing is repair or healing of a laceration.

### Claim 24 (depends on 1, 6)

A wound dressing comprising a peptide according to claim 1 or a polynucleotide according to claim 6.
